Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRY-382 + Pembrolizumab in Advanced Solid Tumors
NCT02880371Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARRY-382 in solid tumor (advanced stage), ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), sponsored by Pfizer. Started Sep 2016; status: terminated.
02
Drugs
ARRY-382
03
Conditions
solid tumor (advanced stage)ovarian cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02880371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880371.